Videos

The internal medicine physician, and chief medical officer and head of development at Pear Therapeutics discussed the findings of a recent study assessing cognitive behavioral therapy for insomnia. [WATCH TIME: 4 minutes]

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]

The Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic discussed the complexities with identifying viable biomarkers for Parkinson disease, as well as interventions geared toward specific regions of the brain. [WATCH TIME: 4 minutes]

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided insight on the lingering questions about GFAP and sTREM2 astrocytes, and their immunologic correlations with Alzheimer disease and related dementias. [WATCH TIME: 4 minutes]

The associate director of the Sleep Center at Children’s Hospital of Philadelphia discussed the detrimental effects poor sleep can have on children, both neurologically and on quality of life. [WATCH TIME: 4 minutes]

Drs Hesham Abboud and Benjamin Greenberg share their approach to treatment selection and highlight the importance of individualizing treatment and patient education.

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, discuss the prevelance of multiple sclerosis and comment on the mechanisms of action and available drug classes utilized in disease management.

Experts in neurology provide insight into the impact multiple sclerosis can have on patients and hypothesize about initiating treatment before cognitive impairment is observed.

Ahmed Obeidat, MD, PhD; Randall Schapiro, MD, FAAN; and Jeffrey Wilken, PhD, discuss the impact of polypharmacy on cognitive health and share their thoughts on deciding when to cease treatments in patients with multiple sclerosis.

The Edward F. and Barbara A. Bell Endowed Chair at the Cleveland Clinic detailed how a new virtual reality tool elucidates prodromal symptoms from patients with Parkinson disease. [WATCH TIME: 3 minutes]

The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending August 20, 2022. [WATCH TIME: 4 minutes]

The chair of the American Migraine Foundation spoke about the insight gleaned from a recent survey the foundation conducted assessing links between mental health and migraine care. [WATCH TIME: 4 minutes]

Dr Williams discusses best practices for taking care of patients with migraine in a collaborative manner.

A migraine specialist cautions against going through migraine treatments quickly and not utilizing their full potential.

Dr Kita Williams shares her strategy for management of AEs with migraine treatments.

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed research on the use of GFAP and sTREM2 in discerning dementia with Lewy bodies from Alzheimer disease. [WATCH TIME: 4 minutes]

The postdoctoral researcher at King’s College London provided background on why gene therapies have not seen as much success in treating ALS, and the need for additional validation of genetic mutations. [WATCH TIME: 3 minutes]

The Edward F. and Barbara A. Bell Family Endowed Chair at Cleveland Clinic discussed seamless adjustment made by patients with Parkinson disease to virtual reality, and the benefits it may bring to care. [WATCH TIME: 4 minutes]

The postdoctoral researcher at King’s College London provided insight on the immunologic differences between genes linked with ALS, and the important aspects to consider for gene-targeted therapies. [WATCH TIME: 3 minutes]

The coauthors of a study assessing costs associated with unused disease-modifying therapies shared their insight into the extended effects of unused treatments in MS, including the importance of transparency between physician and patient. [WATCH TIME: 12 minutes]

Drs Randall Schapiro and Jeffrey Wilken provide insight into the risk factors and disease progression noted in patients with multiple sclerosis.

Experts in neurology comment on the lack of definition of cognitive impairment in multiple sclerosis, highlighting an inability to adequately screen for and measure this disease symptom.

The postdoctoral researcher at King’s College London discussed the mechanistic role SARM1 gene mutations play in the development and progression of ALS. [WATCH TIME: 3 minutes]

The Edward F. and Barbara A. Bell Family Endowed Chair at the Cleveland Clinic provided an overview of the Cleveland Clinic Virtual Reality Shopping platform, a virtual reality tool for Parkinson disease. [WATCH TIME: 5 minutes]

The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]

Neurology News Network for the week of August 13, 2022. [WATCH TIME: 4 minutes]

The associate professor of neuropsychology at the University of Miami Miller School of Medicine provided insight on how persistent impairments seen on a cognitive screening tool may differentiate cognitive status. [WATCH TIME: 6 minutes]

Drs Jeffrey Dunn and Regina Berkovich review available tools and resources for the care of patients with multiple sclerosis, focusing on specific symptoms.

Experts in neurology explore the benefits of a collaborative care approach for patients with multiple sclerosis.